Epilepsy Drugs May Blunt Birth Control, Study Finds

A new study is flagging a hidden collision between two common prescriptions: certain epilepsy medications may quietly reduce the effectiveness of hormonal birth control, leaving patients exposed to unplanned pregnancy for months without realizing it. The research, published October 7, 2026, in the journal Neurology, examined the medical records of 21,923 people with epilepsy who were prescribed hormonal contraceptives alongside enzyme-inducing antiseizure medications, according to News-Medical and Medical Xpress.

The numbers are striking. Nearly one third of the patients studied, 7,154 people or 32.6 percent, had at least one period of 14 days or longer in which a susceptible contraceptive overlapped with an interacting epilepsy drug. Those overlap periods averaged about seven months. That is seven months in which birth control may have been working less well than the patient believed, with no obvious signal that anything was wrong.

How the interaction works

The problem comes down to liver enzymes. A group of widely used antiseizure drugs, including carbamazepine, phenytoin, phenobarbital, oxcarbazepine and topiramate, rev up the liver enzymes that break down hormones. Hormonal contraceptives rely on maintaining steady hormone levels to prevent ovulation, so when those levels are cleared faster than expected, the contraceptive margin of safety shrinks. The study found the interaction can affect combined and progestin-only pills, patches, vaginal rings and subdermal implants, as reported by News-Medical.

Importantly, not all contraception is affected. Intrauterine devices, which work locally rather than through systemic hormone levels, are not subject to the interaction and may be an option for patients taking these medications, according to the reporting. The study was funded by the National Institutes of Health, and its lead author is Dr. Laura Kirkpatrick of the University of Pittsburgh.

One crucial caveat: the researchers measured overlapping prescriptions, not actual contraceptive failures. The study did not track how many unplanned pregnancies resulted from the interaction, so it establishes the scale of the exposure rather than the rate of harm. That distinction matters, but it does not make the finding reassuring. A seven-month average overlap is a long time to be under-protected, and the study suggests the problem is systematic rather than rare, in a year when young patients are already navigating confusing health information.

What patients should do

The takeaway is not to stop taking epilepsy medication. Seizure control is non-negotiable, and abruptly changing antiseizure drugs can be dangerous. The takeaway is to have a specific conversation: anyone taking carbamazepine, phenytoin, phenobarbital, oxcarbazepine, topiramate or similar enzyme-inducing drugs should ask their neurologist and their gynecologist, together, whether their contraception is affected and what alternatives fit their situation.

That conversation too often does not happen. Neurology and reproductive health are handled by different specialists, in different appointments, with different charts, and drug interaction warnings do not always survive the handoff. The study's authors are essentially documenting a coordination failure in modern medicine: each prescription made sense on its own, and the combination quietly undermined one of them. For young women managing both epilepsy and birth control, that gap is exactly the kind of blind spot that can change a life.

Clinicians are starting to pay attention. Professional guidelines have long noted the interaction between enzyme-inducing antiseizure medications and hormonal birth control, but guidance only helps if it reaches the exam room. The study's scale, more than twenty-one thousand patient records, makes it one of the largest real-world snapshots of the problem, and its publication in a major neurology journal puts the issue in front of the specialists most likely to miss it. Pharmacists can help too: a medication review at the pharmacy counter is often the last checkpoint before a new prescription goes home, and asking about birth control there costs nothing.

There is a broader pattern here worth noticing. As more young adults manage multiple chronic conditions with multiple prescriptions, interactions that fall between specialties become more common and more consequential. The fix is unglamorous but effective: medication reviews that look at the whole list, not just one doctor's slice of it, and direct questions about birth control in neurology appointments. Patients should not have to connect these dots themselves, but until the system does it reliably, asking the question is the best protection available. The findings were published in Neurology on October 7, and the authors say clinician awareness is the immediate next step.

The sources for this story are News-Medical and Medical Xpress, reporting on the study published October 7, 2026.